Lariam (Mefloquine Hydrochloride)

Mefloquine interferes with the malaria parasite’s ability to detoxify heme, a toxic by‑product of hemoglobin digestion. By disrupting this pathway and compromising parasite membrane function, toxic heme accumulates, leading to parasite death and clearance of the infection.

The dosing regimen for Lariam is individualized by a qualified prescriber based on the indication, patient weight, age, and regional resistance patterns. Healthcare professionals determine the appropriate loading and maintenance doses, as well as the duration of therapy, to ensure efficacy and safety.

Safety data for mefloquine in pregnancy are limited, and the drug is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult a healthcare provider, as mefloquine can be excreted in breast milk.

To request Lariam, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Lariam (mefloquine) offers weekly dosing for prophylaxis, which can be convenient compared with daily regimens like atovaquone‑proguanil or doxycycline. However, it has a higher incidence of neuropsychiatric side effects. Choice of therapy depends on individual risk factors, drug resistance patterns, and tolerance to potential adverse effects.

Lariam tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect them from moisture and excessive heat. Keep the container tightly closed and out of direct sunlight to maintain product stability.

Lariam is taken orally with a full glass of water. For prophylaxis, a loading dose is usually taken one week before travel, followed by weekly maintenance doses during exposure and for four weeks after leaving the endemic area. For treatment, the prescriber determines the exact schedule based on infection severity.

The most serious risks include neuropsychiatric reactions such as severe anxiety, depression, psychosis, or suicidal thoughts, as well as cardiac arrhythmias in patients with QT prolongation. Rare but severe allergic reactions and hepatic injury may also occur, requiring immediate medical attention.

Lariam is contraindicated in individuals with known hypersensitivity to mefloquine or related quinoline compounds, a history of seizures, severe psychiatric disorders, or significant cardiac conditions that predispose to QT prolongation. Patients with these conditions should discuss alternative antimalarial options with their healthcare provider.